Edition:
India

Bellicum Pharmaceuticals Inc (BLCM.OQ)

BLCM.OQ on NASDAQ Stock Exchange Global Market

10.00USD
17 Nov 2017
Change (% chg)

$0.27 (+2.77%)
Prev Close
$9.73
Open
$9.73
Day's High
$10.24
Day's Low
$9.73
Volume
92,278
Avg. Vol
161,872
52-wk High
$22.98
52-wk Low
$7.42

Chart for

About

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of... (more)

Overall

Beta: --
Market Cap(Mil.): $377.79
Shares Outstanding(Mil.): 33.23
Dividend: --
Yield (%): --

Financials

BRIEF-Bellicum reports qtrly earnings per share loss‍ $0.71​

* Bellicum Pharmaceuticals Inc qtrly earnings per share loss‍ $0.71​

08 Nov 2017

BRIEF-Bellicum Pharmaceuticals enters a cancer research grant contract with cancer prevention and research institute of Texas

* Bellicum Pharmaceuticals says ‍on Aug. 9, entered a cancer research grant contract with cancer prevention and research institute of Texas

16 Aug 2017

BRIEF-Bellicum Pharmaceuticals qtrly loss per share $0.74

* Bellicum pharmaceuticals reports second quarter 2017 financial results and provides corporate update

09 Aug 2017

BRIEF-Bellicum Pharmaceuticals files for mixed shelf offering of upto $150 mln

* Bellicum Pharmaceuticals Inc files for mixed shelf offering of upto $150 million - sec filing Source text: (http://bit.ly/2tmwwmp) Further company coverage:

29 Jun 2017

BRIEF-Bellicum Pharmaceuticals files prospectus relating to disposition of up to about 5 million shares

* Bellicum Pharmaceuticals files prospectus relating to disposition of up to about 5 million shares of co's common stock held by the selling stockholders

29 Jun 2017

Earnings vs. Estimates